Brought to you by 
Exelixis signs debt deal with Deerfield; expired
12 Mar 2010
Executive Summary
Under a facility it is setting up with several funds of the investment group Deerfield Management, Exelixis (clinical-phase cancer candidates) has the option to borrow up to $150mm at 6.75% over the next 18 months.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Withdrawn
Deal Type
-
Financing
- Convertible Debt
- Other
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Exelixis signs debt deal with Deerfield; expired
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice